Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Alnylam Pharmaceuticals (ALNY)

Alnylam names Pushkal Garg chief R&D officer, combines research and development units

Neutral Impact 3 of 5 leadership Written later

Alnylam said it is combining its Research and Early Development and Development functions into one R&D organization, with Pushkal Garg, M.D., appointed Executive Vice President, Chief Research and Development Officer. The filing also sets new pay terms for Garg and Kevin Fitzgerald, Ph.D., who takes on added responsibility for external innovation, which shows how the company is structuring its leadership for pipeline work.

Key points

  • Pushkal Garg, M.D., moves from Chief Medical Officer, EVP, Development and Medical Affairs to EVP, Chief Research and Development Officer.
  • Garg's base salary is set at $825,000, with a target annual incentive of 65% of base salary.
  • Kevin Fitzgerald, Ph.D., gets a target annual incentive raised to 60% of base salary and a one-time restricted stock unit award with a grant date value of $2.5 million, effective July 1, 2025.
  • The Committee approved the changes on June 12, 2025, and the company issued a press release on June 18, 2025.

The filing

CompanyAlnylam Pharmaceuticals (ALNY)
Form8-K, current report
Filed with the SECJun 18, 2025, 4:48 PM ET
Accession number0001178670-25-000076

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 18, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.